Dr. Michael Tuttle on Dosimetry Versus Empiric Dosing Radioactive Iodine Treatment
Michael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.
Michael Tuttle, MD, endocrinologist Memorial Sloan Kettering (MSK), discusses best management approaches to radioactive iodine treatment in patients with radioiodine avid distant metastases from differentiated thyroid cancer.
MSK utilizes individualized whole body/blood clearance dosimetry. To understand how this method compares to empiric fixed dosing, MSK partnered with Gustave Roussy Institute of Oncology in France, which utilizes the fixed dosing method.
By studying patients treated at both centers, it was determined that overall survival rate were similar and there was no significant advantage to either method, says Tuttle. Because dosimetry is more expensive and time-consuming it was concluded based on this study that it does not need to be used in every case.
Anticipating Novel Options for the RAI-Refractory DTC Armamentarium
May 15th 2023In season 4, episode 6 of Targeted Talks, Warren Swegal, MD, takes a multidisciplinary look at the RAI-refractory differentiated thyroid cancer treatment landscape, including the research behind 2 promising systemic therapy options.
Listen
